HOME >> BIOLOGY >> NEWS
Arthritis drug suppresses cancer development by stopping action of key protein

TORONTO - Researchers at The University of Texas M. D. Anderson Cancer Center have, for the first time, identified the molecular pathway by which a commonly prescribed arthritis medication inhibits the growth of cancer.

Before this study, scientists had linked use of celecoxib capsules (commonly known as Celebrex) to prevention of cancer, but the way in which the medication acted in cancer cells was unknown.

Now, investigators have found that celecoxib capsules stop a key transcription factor known as Sp1 from turning on multiple genes in cancer cells known to be associated with cancer growth. One of those genes triggers production of vascular endothelial growth factor (VEGF), the predominant angiogenic factor that leads blood vessels to grow to feed tumors.

The findings were published in the Proceedings for the 2003 Annual Meeting of the American Association for Cancer Research.

"Our results provide a novel molecular mechanism for the antitumor activity of celecoxib," says Keping Xie, M.D., Ph.D., assistant professor in the department of gastrointestinal medical oncology.

Xie adds that although the study was conducted in models of pancreatic cancer, the results likely describe how celecoxib interferes with development of a number of common cancers that all involve the Sp1/VEGF pathway.

"Pancreatic cancer overexpresses Sp1, which then drives VEGF overexpression," says Xie. "This same molecular activity is also found in colon, prostate, gastric and breast cancer."

Now that the mechanism by which celecoxib inhibits cancer growth is known, it may be possible to tailor the drug to be even more powerful, Xie says. Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) known as a cox-2 inhibitor, and this new study demonstrates that cox-2 inhibits VEGF through the Sp1 transcription factor.

The researchers used both pancreatic cell cultures and an animal model of the disease to draw their conclu
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
7-Apr-2003


Page: 1 2

Related biology news :

1. Novel therapeutic target identified in fight against Rheumatoid Arthritis
2. UNC Researchers Reduce Arthritis Severity By Turning Off Molecular Switch
3. NIEHS Finds Protein That Counteracts Inflammation And Wasting That May Target Rheumatoid Arthritis And Crohns Disease
4. Naturally Produced Enzyme May Be Useful In Inflammatory Arthritis
5. First Evidence That Localized Arthritis Gene Therapy Heals Distant Diseased Joints
6. Structure Of Tumor Necrosis Factor-Alpha-Converting Enzyme Solved - Milestone Toward Rational Drug Design For Rheumatoid Arthritis And Endotoxic Shock
7. Animal studies show CA4P suppresses development and induces regression of ocular neovascularization
8. Peptide suppresses multiple sclerosis-like disease
9. HIV selectively suppresses anti-HIV defense cells
10. UPCI presents study on discovery of protein that suppresses dendritic cells
11. Oral administration of estrogen replacement therapy suppresses the biological actions of growth hormones in GH-deficient women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today ... by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the ... and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... ... that demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise control device ... The study reported that the Neoasis™ device attenuated the alarm sounds from patient ...
(Date:7/10/2020)... CHICAGO (PRWEB) , ... July 09, 2020 , ... Today ... Umami Advantage, which will share insight on the “fifth taste” phenomenon that is revolutionizing ... snacks. The Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and ... Known as MediVet Biologics since its formation in 2016, the company is relaunching itself ... will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... can combine up to three different materials for use with CRM, neurostimulation, vascular, ... to three materials to meet specific design requirements, performance, and cost criteria; especially ...
(Date:7/31/2020)... (PRWEB) , ... July 30, ... ... of cloud-based software for the life sciences industry, today announced the release ... platform designed specifically for Medical Science Liaisons (MSLs) and other field medical ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... the early detection and prevention of high-burden diseases, and Centric Consulting, a business ... healthcare organizations to utilize existing data in order to identify and prioritize patients ...
Breaking Biology Technology:
Cached News: